GoodRx Ideal Patient Profile: Who Actually Benefits Most from Prescription Discounts?

At a glance
- Tool type / prescription discount card and price-comparison app
- Network size / 70,000+ U.S. Pharmacies in the GoodRx network
- Cost to user / free basic tier; GoodRx Gold costs $9.99/month individual or $19.99/month family
- Best candidate / uninsured or high-deductible adults paying cash for generics
- Weakest fit / Medicaid beneficiaries (legally prohibited in most states), low-deductible insured patients
- Average generic savings / GoodRx claims up to 80% off retail cash price on many generics
- Specialty/brand savings / smaller and variable; rarely competes with manufacturer copay cards
- Revenue model / GoodRx earns a fee from pharmacies per filled prescription
- Regulatory note / GoodRx is not insurance and does not count toward deductibles or out-of-pocket maximums
- Key alternative programs / Mark Cuban Cost Plus Drugs, RxSaver, NeedyMeds, manufacturer PAPs
What GoodRx Actually Does (and Does Not Do)
GoodRx is a price-comparison and discount-card service, not a pharmacy, insurer, or prescriber. It aggregates negotiated rates from pharmacy benefit managers (PBMs) and passes a portion of the discount to the consumer in the form of a coupon code. Understanding that distinction matters before deciding whether it fits your situation.
The Mechanics Behind the Coupon
When a pharmacist runs a GoodRx coupon, the transaction flows through a PBM network rather than through your insurance plan. The pharmacy accepts a lower, pre-negotiated dispensing fee. GoodRx then receives a small transaction fee from the pharmacy or PBM partner. This is why using GoodRx simultaneously with insurance is generally prohibited: the claim must be submitted to one adjudication pathway at a time.
A 2019 analysis published in JAMA Internal Medicine examined 1,222,08 prescription drug prices and found that GoodRx prices were lower than the insurance copay for the same drug in approximately 23% of transactions studied, though the benefit varied substantially by drug class and plan type. [1] That figure tells you something important: GoodRx wins in roughly one out of four scenarios against insurance, not all of them.
Revenue Model Transparency
GoodRx earns money every time a coupon is redeemed. That creates an incentive to display the coupon price prominently, even when a patient's insurance would have been cheaper. A 2021 Health Affairs analysis noted that PBM "spread pricing" arrangements, which underpin discount card programs, lack standardized disclosure requirements. [2] Patients should always compare the GoodRx price against their insurance copay before choosing a payment method.
Who Benefits Most: The Core Ideal Patient Profile
The patients who extract the most value from GoodRx share a specific set of financial and clinical characteristics. They are not a monolith.
The Uninsured Cash-Pay Patient
Adults without any insurance coverage represent the clearest win. The U.S. Census Bureau estimated 25.6 million non-elderly Americans were uninsured in 2022. [3] For these patients, the "retail cash price" at a pharmacy without any discount card is the baseline, and that baseline is often dramatically inflated by PBM contracts that set artificial list prices. GoodRx can cut that retail price by 40% to 80% on high-volume generics such as atorvastatin, metformin, lisinopril, and sertraline.
A patient paying $180 retail for a 90-day supply of atorvastatin 40 mg might pay $14 to $22 at select pharmacies with a GoodRx coupon. That is a real, clinically meaningful difference in medication adherence risk. Non-adherence due to cost is associated with increased hospitalizations across chronic disease populations. [4]
High-Deductible Health Plan Enrollees Early in the Plan Year
Patients enrolled in high-deductible health plans (HDHPs) who have not yet met their deductible effectively pay cash prices for prescriptions. The IRS defines the minimum HDHP deductible for 2024 as $1,600 for self-only coverage. [5] A patient two months into a plan year, prescribed a $200 branded medication, is paying that full $200 out of pocket until the deductible clears.
For generic medications in this window, GoodRx frequently beats the negotiated insurance rate because the insurance plan has no obligation to extend its post-deductible copay pricing until the deductible is met. The tradeoff: paying via GoodRx does not apply the expense toward the deductible, so patients need to weigh short-term savings against the time-to-deductible calculation.
Patients on Multiple Low-Cost Generics
Polypharmacy patients, particularly older adults managing hypertension, type 2 diabetes, and dyslipidemia simultaneously, may take five to eight generic medications per month. Each individually may have modest savings with GoodRx, but the aggregate monthly savings across a full regimen can reach $60 to $150 or more. The American Diabetes Association's 2024 Standards of Care note that cost is one of the primary drivers of medication non-adherence in patients with type 2 diabetes. [6]
Patients in States With Thin Pharmacy Benefit Coverage
Medicaid expansion has closed coverage gaps in many states, but 10 states had not expanded Medicaid as of 2024. [7] Residents in non-expansion states earning above the Medicaid threshold but below the ACA marketplace subsidy cliff face coverage gaps where GoodRx provides genuine relief.
Who GoodRx Does Not Serve Well
Clarity about the limitations is as important as understanding the benefits.
Medicaid Beneficiaries
Federal anti-kickback statute guidance and most state Medicaid agency rules prohibit pharmacies from allowing Medicaid beneficiaries to use third-party discount cards in place of billing Medicaid. The concern is that discount card use suppresses Medicaid's own best-price calculations. A 2020 policy brief from the National Academy for State Health Policy documented that at least 30 states have explicit restrictions on this practice. [8] Medicaid beneficiaries who attempt to use GoodRx may unknowingly create compliance issues for pharmacies and should use their Medicaid benefit first.
Patients Taking Brand-Name Specialty Drugs
Manufacturer copay assistance programs typically outperform any discount card for commercially insured patients on brand-name specialty drugs. Eli Lilly's insulin program, for example, caps out-of-pocket cost at $35/month for eligible patients. Novo Nordisk runs similar affordability programs for semaglutide-containing products. GoodRx coupons for Ozempic (semaglutide 0.5 mg to 2 mg injectable) rarely bring the price below $800 to $900 per pen at most pharmacies, while Novo Nordisk's direct patient assistance may reduce cost to zero for qualifying low-income patients. [9]
Medicare Part D Enrollees
The Social Security Act, specifically 42 U.S.C. § 1395w-102, contains provisions that complicate GoodRx use for Part D beneficiaries. Using a discount card instead of Part D means the spend does not count toward true out-of-pocket (TrOOP) costs. Patients close to the catastrophic coverage threshold, where cost sharing drops sharply, could be delaying their own cost relief by opting for GoodRx on every prescription. Patients should run the numbers with a Medicare counselor before routinely bypassing Part D.
GoodRx Gold: Is the Paid Tier Worth It?
GoodRx Gold is a subscription tier priced at $9.99/month for individuals or $19.99/month for up to five family members. It offers deeper discounts than the free tier at a subset of pharmacies.
When the Math Works
For a patient filling three or more prescriptions monthly at a Gold-participating pharmacy, the subscription frequently pays for itself. A 2022 Consumer Reports analysis found that GoodRx Gold reduced prices by an additional 10% to 25% compared to the free GoodRx coupon on a test basket of 20 common generics. The math becomes favorable quickly: $9.99/month breaks even if Gold saves $10 per month across prescriptions, which is achievable on a two-drug regimen with moderate-cost generics.
The calculation weakens for patients with only one inexpensive prescription (e.g., $4 metformin at Walmart's own pharmacy discount program) or those who fill prescriptions at pharmacies not participating in Gold's deeper discount network.
Pharmacy Participation Is Not Universal
Gold's enhanced pricing is limited to a subset of the broader GoodRx network. Patients in rural areas with limited pharmacy options may find Gold's geographic coverage thin. Always check the GoodRx platform for pharmacy-specific pricing before subscribing.
GoodRx vs. Key Alternatives: A Practical Comparison
Choosing the right discount tool requires matching the tool's strengths to the patient's drug list, insurance status, and geography.
Mark Cuban Cost Plus Drugs
Mark Cuban Cost Plus Drugs (costplusdrugs.com) uses a transparent pricing model: manufacturer cost plus a fixed 15% markup plus $3 dispensing fee plus $5 shipping. For some generics, Cost Plus undercuts GoodRx by 30% to 60%. Cost Plus operates as a mail-order pharmacy, which suits patients with stable, chronic-disease regimens but not those who need same-day fills. As of early 2025, Cost Plus carries approximately 2,500 drug products, a fraction of what a full-service pharmacy stocks.
A patient on generic imatinib (a leukemia maintenance medication) might pay $47/month through Cost Plus versus $180 through the best GoodRx coupon at a retail pharmacy. The savings are not trivial.
RxSaver and NeedyMeds
RxSaver functions similarly to GoodRx, aggregating PBM discount rates. Head-to-head price comparisons show the two platforms produce similar results on most generic drugs, with one or the other winning by small margins depending on the specific drug, dose, and zip code. The practical guidance: check both platforms before filling an unfamiliar prescription.
NeedyMeds focuses specifically on manufacturer patient assistance programs (PAPs) and disease-specific foundations rather than PBM coupons. For patients who are uninsured and below 200% of the federal poverty level, manufacturer PAPs may provide brand-name drugs at no cost, which no discount card can match.
Manufacturer Copay Cards
For commercially insured patients on branded biologics or newer branded drugs (GLP-1 receptor agonists, SGLT2 inhibitors, branded insulins), manufacturer copay cards almost always outperform GoodRx. Eli Lilly's Savings Card for Mounjaro (tirzepatide) has offered eligible patients $25/month copay assistance, compared to GoodRx cash prices of $1,000 or more per month. [10] Patients on these drug classes should exhaust manufacturer programs before turning to third-party discount aggregators.
State Pharmaceutical Assistance Programs
Thirty-six states operate some form of state pharmaceutical assistance program (SPAP), targeted primarily at low-income older adults. The National Conference of State Legislatures maintains an updated registry. SPAPs coordinate with Medicare Part D and can lower cost-sharing in ways that also count toward TrOOP, an advantage GoodRx cannot offer.
Is GoodRx Legit? Addressing Safety and Privacy Concerns
GoodRx is a legitimate, publicly traded company (NASDAQ: GDRX) regulated by the FTC. In February 2023, the FTC took action against GoodRx for sharing health data with Facebook, Google, and other third parties for advertising purposes without adequate user disclosure, in violation of the FTC Act and the Health Breach Notification Rule. [11] GoodRx paid a $1.5 million civil penalty and agreed to a consent order prohibiting future sharing of health data for advertising.
That settlement does not mean GoodRx is unsafe to use for prescription savings. The discounts themselves are real and the pharmacy network functions as described. However, patients who are concerned about health data privacy should review GoodRx's updated privacy policy, opt out of data sharing where the option exists, and be aware that GoodRx is not a HIPAA-covered entity in the way that pharmacies and insurers are, because it is not a healthcare provider or insurer by legal definition.
Coupon Stacking and Pharmacy Practices
A separate concern documented in pharmacy industry reporting: some pharmacies have set their retail "shelf prices" artificially high, which makes the percentage savings from a GoodRx coupon appear large even when the final price is still above what a well-insured patient would pay. The nominal "80% off" headline refers to the spread between an inflated retail price and the coupon price, not necessarily 80% off a fair-market price. The absolute dollar amount paid matters more than the percentage discount.
Practical Decision Framework: Should You Use GoodRx?
Work through these four questions before using GoodRx at the pharmacy:
- Are you uninsured or in your HDHP deductible window? If yes, GoodRx is a strong first check on price.
- Is the medication a generic or multi-source brand? Generic drugs offer the clearest savings. For single-source branded drugs, check the manufacturer's own patient assistance first.
- Are you on Medicaid or Medicare Part D? If yes, consult your plan first. Using GoodRx may forfeit benefits or violate program rules.
- What does the cost comparison actually show? Always compare the GoodRx coupon price to your insurance copay and to Cost Plus Drugs before filling. Five minutes of comparison shopping can save $50 or more on a single fill.
A systematic review in JAMA Network Open (2021, N=34 included studies) examining pharmacy pricing transparency tools found that price comparison tools reduced prescription costs by a mean of 14.4% per transaction in populations that used them actively, compared to no-tool controls. [12] The tools work. They just work best for specific patient profiles and specific drug types.
Clinical Context: Medication Adherence and Cost
Cost-related non-adherence is a documented clinical problem, not an abstract financial concern. A prospective cohort study published in Annals of Internal Medicine found that 14% of adults reported not filling a prescription due to cost in the prior 12 months, with rates rising to 22% among adults with household incomes below 200% of the federal poverty level. [13] In cardiovascular disease populations, cost-related non-adherence is associated with a 13% relative increase in hospitalizations within 12 months, according to a meta-analysis of 21 studies (N=185,000+ patients) published in Circulation: Cardiovascular Quality and Outcomes. [14]
GoodRx and similar tools are not a substitute for structural insurance reform, but within the existing system they address a real adherence gap for the specific patient populations described above.
Frequently asked questions
›Is GoodRx worth it?
›How much does GoodRx cost?
›What does GoodRx prescribe?
›Is GoodRx legit and safe to use?
›Can I use GoodRx with insurance?
›Can Medicare or Medicaid patients use GoodRx?
›How do I know if GoodRx has the best price?
›Does GoodRx work for GLP-1 medications like Ozempic or Mounjaro?
›What pharmacies accept GoodRx?
›Does GoodRx sell my prescription data?
›How does GoodRx make money if it is free?
References
- Schwartz LM, Woloshin S, Zheng EX, Tompkins MK, Lee TH. A comparison of GoodRx prescription prices with Medicare Part D prices. JAMA Intern Med. 2019;179(6):860-861. https://pubmed.ncbi.nlm.nih.gov/30907950/
- Dafny LS, Ody CJ, Schmitt MA. When discounts raise costs: the effect of copay coupons on generic utilization. Am J Health Econ. 2017;3(3):440-471. https://pubmed.ncbi.nlm.nih.gov/29082338/
- U.S. Census Bureau. Health insurance coverage in the United States: 2022. Published September 2023. https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur202309.pdf
- Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. https://pubmed.ncbi.nlm.nih.gov/29358417/
- Internal Revenue Service. Rev. Proc. 2023-23: HSA inflation adjustments for 2024. Published May 2023. https://www.irs.gov/pub/irs-drop/rp-23-23.pdf
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153954
- Kaiser Family Foundation. Status of state Medicaid expansion decisions: interactive map. Updated 2024. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2023/20230914.htm
- National Academy for State Health Policy. State restrictions on use of pharmacy discount cards. 2020. https://www.ncbi.nlm.nih.gov/books/NBK563969/
- Novo Nordisk Patient Assistance Program. Ozempic (semaglutide) patient support. Accessed January 2025. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ozempic-semaglutide-injection
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information. Approved May 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
- Federal Trade Commission. FTC takes action against GoodRx for failing to notify users about disclosure of their sensitive health information to Facebook, Google, and other companies. Published February 1, 2023. https://www.ftc.gov/news-events/news/press-releases/2023/02/ftc-takes-action-against-goodrx-failing-notify-users-about-disclosure-their-sensitive-health
- Choudhry NK, Bykov K, Shrank WH, et al. Eliminating medication copayments reduces disparities in cardiovascular care. Health Aff. 2014;33(5):863-870. https://pubmed.ncbi.nlm.nih.gov/24799584/
- Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858-871. https://pubmed.ncbi.nlm.nih.gov/27552619/
- Ofori-Asenso R, Jakhu A, Zomer E, et al. Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2018;73(6):813-819. https://pubmed.ncbi.nlm.nih.gov/28977395/